Literature DB >> 30105925

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Graziela Z Dal Molin1, Shannon N Westin1, Robert L Coleman1.   

Abstract

Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in approval of rucaparib for patients with both germline and somatic BRCA mutation. Data from the Phase III trial ARIEL3 led to approval in platinum-sensitive disease as maintenance. This article reviews the efficacy, safety, pharmacokinetics and pharmacodynamics of rucaparib as well as future and ongoing trials.

Entities:  

Keywords:  BRCA mutated ovarian cancer; PARP; company tests; ovarian cancer; ovarian cancer maintenance treatment; platinum sensitive ovarian cancer; poly (ADP-ribose) polymerase inhibitors; rucaparib

Mesh：

Substances：

Year:  2018        PMID： 30105925      PMCID： PMC6331693          DOI： 10.2217/fon-2018-0215

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  37 in total

1.  Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Authors:  Yvette Drew; Evan A Mulligan; Wan-Tse Vong; Huw D Thomas; Samra Kahn; Suzanne Kyle; Asima Mukhopadhyay; Gerrit Los; Zdenek Hostomsky; Elizabeth R Plummer; Richard J Edmondson; Nicola J Curtin
Journal:  J Natl Cancer Inst       Date:  2010-12-23       Impact factor: 13.506

Review 2.  PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.

Authors:  Angiolo Gadducci; Maria Elena Guerrieri
Journal:  Crit Rev Oncol Hematol       Date:  2017-04-20       Impact factor: 6.312

3.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

4.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Authors:  Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

5.  In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.

Authors:  Alex McCormick; Helen Swaisland
Journal:  Xenobiotica       Date:  2016-10-26       Impact factor: 1.908

6.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

7.  Update on first-line treatment of advanced ovarian carcinoma.

Authors:  Z Kemp; Ja Ledermann
Journal:  Int J Womens Health       Date:  2013-01-25

8.  Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.

Authors:  J M Cunningham; M S Cicek; N B Larson; J Davila; C Wang; M C Larson; H Song; E M Dicks; P Harrington; M Wick; B J Winterhoff; H Hamidi; G E Konecny; J Chien; M Bibikova; J-B Fan; K R Kalli; N M Lindor; B L Fridley; P P D Pharoah; E L Goode
Journal:  Sci Rep       Date:  2014-02-07       Impact factor: 4.379

9.  Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Authors:  Amit M Oza; Anna V Tinker; Ana Oaknin; Ronnie Shapira-Frommer; Iain A McNeish; Elizabeth M Swisher; Isabelle Ray-Coquard; Katherine Bell-McGuinn; Robert L Coleman; David M O'Malley; Alexandra Leary; Lee-May Chen; Diane Provencher; Ling Ma; James D Brenton; Gottfried E Konecny; Cesar M Castro; Heidi Giordano; Lara Maloney; Sandra Goble; Kevin K Lin; James Sun; Mitch Raponi; Lindsey Rolfe; Rebecca S Kristeleit
Journal:  Gynecol Oncol       Date:  2017-09-04       Impact factor: 5.482

10.  PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.

Authors:  J Farrés; L Llacuna; J Martin-Caballero; C Martínez; J J Lozano; C Ampurdanés; A J López-Contreras; L Florensa; J Navarro; E Ottina; F Dantzer; V Schreiber; A Villunger; O Fernández-Capetillo; J Yélamos
Journal:  Cell Death Differ       Date:  2014-12-12       Impact factor: 15.828
View more
  4 in total

1.  A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report.

Authors:  Yunke Huang; Jing Xu; Ke Li; Jing Wang; Yilin Dai; Yu Kang
Journal:  Cancer Manag Res       Date:  2021-03-29       Impact factor: 3.989

Review 2.  Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.

Authors:  Iain A Richard; Joshua T Burgess; Kenneth J O'Byrne; Emma Bolderson
Journal:  Front Cell Dev Biol       Date:  2022-01-14

3.  Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.

Authors:  Linzhi Han; Hongjie Shi; Yuan Luo; Wenjie Sun; Shuying Li; Nannan Zhang; Xueping Jiang; Yan Gong; Conghua Xie
Journal:  Cancer Med       Date:  2020-10-24       Impact factor: 4.452

4.  CIRCNV: Detection of CNVs Based on a Circular Profile of Read Depth from Sequencing Data.

Authors:  Hai-Yong Zhao; Qi Li; Ye Tian; Yue-Hui Chen; Haque A K Alvi; Xi-Guo Yuan
Journal:  Biology (Basel)       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.